Research programme: lysosomal storage disease therapeutics - Oxyrane
Alternative Names: LSD 2; LSD 3; LSD 4; LSD 5; OXY-2810Latest Information Update: 28 Feb 2025
At a glance
- Originator Oxyrane
- Class Enzymes
- Mechanism of Action Enzyme replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Gaucher's disease
- No development reported Glycogen storage disease type II; Lysosomal storage diseases
Most Recent Events
- 28 Feb 2025 No recent reports of development identified for preclinical development in Glycogen-storage-disease-type-II in United Kingdom (Parenteral)
- 28 Feb 2025 No recent reports of development identified for preclinical development in Lysosomal storage diseases in United Kingdom (Parenteral)
- 26 Feb 2023 Preclinical development is ongoing for Glycogen-storage-disease-type-II in United Kingdom (Oxyrane website; February 2023)